Review of medication-assisted treatment for opioid use disorder.  Ghanem N, Dromgoole D, Hussein A, Jermyn RT.  J Osteopath Med. 2022 Mar 14. doi: 10.1515/jom-2021-0163. Epub ahead of print. PMID: 35285220. https://www.degruyter.com/d...

Update Suchtmedizin: Neue Optionen in der Substitution Zu Substitution stehen heute zahlreiche Substanzen und Darreichungsformen zur Verfügung. In den letzten Jahren sind insbesondere retardierte Präparate hinzu gekommen, so dass mittlerweile ein...

Interim opioid agonist treatment for opioid addiction: a systematic review.  Samsó Jofra L, Puig T, Solà I, Trujols J.  Harm Reduct J. 2022 Jan 29;19(1):7. doi: 10.1186/s12954-022-00592-x. PMID: 35090475; PMCID: PMC8800211. https://ww...

Opioid agonist treatment for self-harm and suicide prevention Nestadt, Paul S et al. The Lancet Psychiatry, Volume 9, Issue 2, 100 - 101  Abstract https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(21)00448-X/fulltext

A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder.  Chawar C, Hillmer A, Sanger S, D'Elia A, Panesar B, Guan L, Xie DX, Bansal N, Abdullah A, Kapczinski F, Pare G, Thabane L, Samaan Z...

Cost-effectiveness of Treatments for Opioid Use Disorder.  Fairley M, Humphreys K, Joyce VR, et al.  JAMA Psychiatry. 2021;78(7):767–777. doi:10.1001/jamapsychiatry.2021.0247 https://jamanetwork.com/journals/jamapsychiatry/article-abs...